Neurodegenerative disease assay kit INNOTEST® PHOSPHO-TAU (181P)

clinicalbiologicalcerebrospinal fluid

The INNOTEST PHOSPHO-TAU(181P) is a solid-phase enzyme immunoassay for the quantitative determination of phosphorylated Tau (Phospho-Tau(181P)) in human cerebrospinal fluid (CSF). The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression.1-5 The discrimination of AD from non-AD types of dementia such as dementia with Lewy Bodies may be further improved using the quantification of CSF-phospho-Tau(181) Details Advantages of our assays Simple colorimetric immunoassays that are easily automated on microplate-processor Supported by many peer-reviewed scientific publications Less than 300 μL of CSF necessary for determination of complete biomarker profile Assay range consistent with biological range of values Clinical background Alzheimer’s disease (AD) is the most common form of dementia and is histologically characterized by the accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles throughout the brain. The major constituents of amyloid plaques are the β-amyloid peptides consisting of 40 and 42 amino acids, which are derived from the amyloid precursor protein. Neurofibrillary tangles are made up of paired helical filaments consisting of hyperphosphorylated tau protein (phospho-tau). Tau protein, present in the brain in 6 different isoforms, is an intracellular protein that is released upon neuronal death. A license regarding amyloid beta antibodies contained in this product under patents US 570349 and EP 0683234 has been obtained from Takeda Pharmaceutical Company Limited. Furthermore,